Washington ExaminerSig. 8OpinionHealthLawPolitics
The article argues that the FDA has long delayed safety scrutiny of mifepristone and is trying to avoid judicial review of its loosened REMS while pro-life states like Louisiana challenge the rules. It contends the 5th Circuit should let pro-life states sue and rule in their favor.
Washington ExaminerSig. 6OpinionEnergyHealthForeign
The op-ed argues the U.S. should expand domestic production of medical and industrial radioisotopes to avoid dependence on Russia, China, and other foreign suppliers. It points to a new Oklo test reactor in Texas as evidence that streamlined nuclear development can rebuild capacity. It urges regulatory reform while maintaining safety standards.
Washington ExaminerSig. 5NewsHealthPoliticsElections
The op-ed argues that a MAGA Inc. ad in Texas offers Republicans a winning playbook on healthcare by tying Democratic nominee James Talarico's government healthcare expansion to higher taxes and rural hospital closures. It praises Ken Paxton, Greg Abbott, and Texas's Medicaid model while criticizing California and Gavin Newsom as mismanaged and costly.
Washington ExaminerSig. 6OpinionHealthEconomyTrade
An op-ed argues that the Trump administration’s GLOBE and GUARD Medicare pilot programs, meant to stop foreign free-riding on U.S. drug prices, would instead penalize small and mid-size American biotech firms. Because those firms often out-license foreign marketing rights, the piece says they cannot control foreign pricing and would bear costs they cannot recover, potentially reducing innovation and patient access. It urges the administration to confront foreign governments directly rather than penalize U.S. innovators.
Daily MailSig. 4NewsHealth
An 80-year-old man underwent double leg amputation after it took 29 appointments over four years to diagnose peripheral arterial disease. His wife says the delay was 'disgraceful' and that a simple Doppler test could have saved his legs, with the NHS spending over £1 million on his care.
Fox NewsSig. 5OpinionHealthEconomyTrade
This opinion piece argues that Trump's new drug pricing agreements are commendable but insufficient because the root cause of high U.S. drug prices is foreign governments free-riding on American pharmaceutical innovation. It urges the administration to target foreign price controls and rebate policies so other wealthy nations pay more for medicines.
National ReviewSig. 7OpinionElectionsHealthLaw
The editorial urges Virginians to vote against Amendment 1, arguing it is a deceptive and extreme measure that would enshrine broad abortion and transgender rights, eliminate parental consent and legislative safeguards, and prevent future restrictions. It frames the amendment as a permanent power grab that forecloses democratic debate.
Fox NewsSig. 4NewsHealthPolitics
Massachusetts Gov. Maura Healey announced $2.25 million to expand the Welcome Family program, which sends nurses to homes for postpartum screening and support. The article says the taxpayer-funded expansion has sparked online debate over the government’s role in family health care and ties the issue to postpartum mental-health legal debates.
Daily MailSig. 6NewsHealthEconomyPolitics
A survey of GPs found most believe adult ADHD is over-diagnosed, with many reporting that private providers almost never reject a diagnosis. The article links this to rising NHS waits, private fees, benefits claims, and unsustainable costs ahead of a government review.
Washington ExaminerSig. 5OpinionPoliticsHealthCulture
The essay uses Hamlet and baseball's tie-goes-to-the-runner rule to argue that uncertainty about fetal personhood cannot be treated as proof that a fetus is not a person, while also acknowledging the physical and psychological burdens pregnancy imposes on women. It concludes that both continuing and ending a pregnancy carry moral costs and that the level of certainty required depends on how substantial the burden on the woman is.
Washington ExaminerSig. 7OpinionHealthEconomyLaw
An op-ed argues that pharmacy benefit managers and insurers, not drugmakers, are responsible for high prescription drug costs. It contends their lobbying for the ETHIC Act is a blame-shifting effort that would weaken patent protections and discourage research.
NPRSig. 8NewsConflictForeignHealth
Houthi forces' capture of western Yemen has displaced about 125,000 people, shattered a fragile truce, and worsened an already severe humanitarian crisis. Aid groups describe full camps, failing health facilities, and far too little funding as fighting continues around Taiz and Mokha.